Notably, HER2-positive/HR-negative patients showed a numerically higher pCR rate of 63.2% (95% CI 49.3–75.6), suggesting that the cross-talk between hyperactive HR and HER2 pathways significantly influences tumor biology and patient outcomes. The gene discussed is ERBB2; the disease is neoplasm.